Kao (4452) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
15 May, 2026Executive summary
Net sales for Q1 FY2026 reached JPY 413.2 billion, up 6.0% year-over-year and 2.5% like-for-like, driven by volume and price increases.
Operating income surged 45.3% to JPY 44.9 billion, aided by a one-time JPY 11.5 billion gain from land sales; excluding this, operating income rose 8.0%.
Net income attributable to owners increased 35.7% to JPY 31.0 billion; EPS rose 39.3% year-over-year to JPY 68.53.
Growth was led by the Global Consumer Care (GC) Business in Japan and strong contributions from Cosmetics in Asia and Health Beauty Care in the Americas.
The company maintained its full-year earnings forecast and progress on the K27 mid-term plan despite global economic uncertainty and inflationary pressures.
Financial highlights
Net sales increased by 6.0% year-over-year (+JPY 23.4 billion), with gross profit up 7.2% and gross margin rising 0.4 pts to 38.4%.
Operating income rose by JPY 14.0 billion to JPY 44.9 billion (+45.3%), and net income attributable to owners increased by 35.7% to JPY 31.0 billion.
EBITDA grew 28.3% to JPY 67.2 billion.
ROIC improved to 10.1%, up 2.6 percentage points year-over-year.
Comprehensive income swung from a JPY 4.6 billion loss to JPY 43.8 billion, reflecting FX gains.
Outlook and guidance
Full-year consolidated results forecast remains unchanged, with FY2026 net sales forecast at JPY 1,750 billion (+3.6% YoY), operating income JPY 182 billion (+11.3%), and net income attributable to owners JPY 130 billion (+8.3%).
Anticipates profit recovery in the Chemicals segment from Q2 onward as price pass-through improves in the Americas and Europe.
Integrated operations and supply chain resilience are expected to support stable supply and flexible adaptation to market changes.
FY2026 basic EPS forecast at JPY 143.70 (post-share split basis).
Progress toward K27 is on track, with improved prospects for success.
Latest events from Kao
- Profits and sales rose, with a share split and higher dividends planned for FY2026.4452
Q4 20256 Feb 2026 - H1 operating income up 68%, full-year outlook raised, but China remains a challenge.4452
Q2 20242 Feb 2026 - Profit and margin growth surged on reforms and premiumization, offsetting China cosmetics weakness.4452
Q3 202416 Jan 2026 - Profit and ROIC surged on reforms; 2025 targets further growth and global expansion.4452
Q4 20248 Jan 2026 - Operating income jumped 41.9% on 6.6% sales growth, with robust gains in Japan.4452
Q1 20258 Jan 2026 - Profitability and margins rose, driven by high-value products and Cosmetics recovery.4452
Q3 202516 Dec 2025 - Upward forecast revision and major share buyback follow strong H1 results and improved profitability.4452
Q2 202523 Nov 2025